1. Volume 132, Issue 5, Pages 1672-1683 (May 2007)
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial 
Stephan R. Targan, Brian G. Feagan, Richard N. Fedorak, Bret A. Lashner, Remo Panaccione, Daniel H. Present, Martina E. Spehlmann, Paul J. Rutgeerts, Zsolt Tulassay, Miroslava Volfova, Douglas C. Wolf, Chito Hernandez, Jeffrey Bornstein, William J. Sandborn 
Gastroenterology 
Volume 132, Issue 5, Pages (May 2007)
DOI: /j.gastro
Copyright © 2007 American Gastroenterological Association Institute Terms and Conditions

2. Figure 1 Study flow diagram.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2007 American Gastroenterological Association Institute Terms and Conditions

3. Figure 2
Enrollment, treatment, and outcome of patients in the ENCORE trial.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2007 American Gastroenterological Association Institute Terms and Conditions

4. Figure 3
The primary end point was induction of response (≥70-point decrease from baseline CDAI score) at Week 8 that was sustained through Week 12. (A) Proportion of patients with a clinical response (≥70-point decrease from baseline CDAI score). The secondary end points were induction of remission (CDAI score <150) at Week 8 that were sustained through Week 12 and the proportion of patients in response or remission at Week 12. (B) Proportion of patients in clinical remission (CDAI score <150). (C) Proportion of patients with ≥100-point decrease from baseline CDAI score. Significant differences between the treatment groups are noted.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2007 American Gastroenterological Association Institute Terms and Conditions

5. Figure 4
(A) Mean serum CRP concentration (mg/L) at each visit. (B) Mean platelet count (×10 9/L) at each visit. (C) Mean serum albumin concentration (g/L) at each visit. P values reflect a statistically significant difference between treatment groups.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2007 American Gastroenterological Association Institute Terms and Conditions